Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Elevation Oncology, Inc.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient’s unique tumor characteristics. 
 
Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline.

K2 HealthVentures

Aisling Capital

Biotechnology Value Fund

BVF Partners

Vivo Capital

Janus Henderson Investors

venBio Partners

Cormorant Asset Management

Driehaus Capital Management

Samsara BioCapital

Qiming Venture Partners USA

Vertex Ventures HC

Elevation Oncology

Today we announced the appointment of Darcy Mootz, Ph.D., to our Board of Directors. 
 
Darcy Mootz, Ph.D., currently serves as President of Architect Therapeutics, a position she has held since April 2023. She is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations. 
 
https://lnkd.in/eztEX_eY
 
#Oncology #ADC #Innovation

In an interview with Bioprocess Online, Elevation Oncology’s CEO, Joseph Ferra, and CSO, Dr. David Dornan, shared their insights on what made EO-3021 worth licensing and how the company is executing its clinical strategy. 

Discover the factors that Elevation Oncology considered when licensing their lead ADC program, EO-3021, aimed at treating solid tumors that are likely to express Claudin 18.2.

Read the full interview by Tyler Menichiello on Bioprocess Online: https://bit.ly/3vVXK5w

#Oncology #ADC #Licensing #drugdevelopment

Senior writer Adam Feuerstein of STAT delves into Elevation Oncology's impressive market valuation surge in 2024, amidst a wave of investor interest in undervalued ADC companies. This comes as major players invest billions in ADC deals.

Discover more in Adam's insightful column (subscription required): https://bit.ly/4b9RHum

#oncology #valuation #drugdevelopment #marketvaluation

We had a wonderful and productive time at #JPM2024, meeting with other innovators in the healthcare industry to discuss what 2024 has in store and enjoying #SanFrancisco.

Great connecting and catching up with everyone! Until next year! 

#Oncology #ADC #Innovation #Biopharma

Elevation Oncology is excited to present a Trial in Progress poster for the currently enrolling Phase 1 study of EO-3021, a Claudin 18.2 ADC, today at the 2024 ASCO Gastrointestinal Cancers Symposium. 

https://lnkd.in/eJedHj-Q
 
$ELEV #ASCOGI2024 #clinicaltrial #claudin18 #ADC #drugdevelopment #cancer #oncology

Our CEO, Joseph Ferra, had a great conversation with host Matthew Pillar on Bioprocess Online’s Business of Biotech podcast, discussing our potential best-in-class #ADC candidate EO-3021 and the challenges of navigating today’s #biotech market.
 
Podcast website: https://lnkd.in/ekaGDDTV 
 
Listen on Apple podcasts: https://lnkd.in/eaderina
 
Listen on Spotify: https://lnkd.in/eaderina 
 
#Oncology #Innovation #Podcast

Today we announced program updates and upcoming #milestones including:
 
Plans to expand our clinical development program to evaluate EO-3021 in combination. We believe a combination approach has the potential to offer optimal outcomes to patients, particularly in the gastric cancer setting, with both immunotherapy and targeted agents. We expect to share details on our planned Phase 1 combination study in the first half of 2024.
 
HER3-ADC: Our second program is a differentiated HER3-targeting ADC. HER3 is a well-validated ADC target, which is overexpressed across solid tumors and often associated with poor outcomes. There are currently no HER3-targeted ADC agents approved for the treatment of cancer. We’re currently evaluating our HER3-ADC program and plan to nominate a development candidate in 2024.
 
https://lnkd.in/exKQWcXG 
 
#Oncology #Biotech #ADC #Innovation

Wishing a very happy and restful holiday season to our colleagues, partners and the patient communities we aim to serve. We are grateful for your contributions and collaboration. 

Looking forward to 2024!

#HappyHolidays #HappyNewYear #Oncology #Biotech

We had a great time at our in-person meeting in Austin, TX, in November. It was wonderful spending time with everyone, celebrating milestones, and meeting new team members.

We took this time to strategize internally through executive presentations and were excited to give back to the city of Austin by making gift bags for patients at the local children’s hospital.

Looking forward to a great 2024!

#GoTeam #GivingBack #Austin #Oncology #Biotech

November is #StomachCancerAwarenessMonth! Globally, stomach cancer is the fourth most common cancer and the second leading cause of worldwide cancer deaths. In the US alone, an estimated 26.5k new cases of stomach cancer will be diagnosed every year.
 
Learn more about stomach cancer awareness: https://lnkd.in/etQj25R4

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
cost and expenses	5.88M -	17.28M 193.71%	32.05M 85.49%	94.55M 195.04%	40.34M 57.34%
cost of revenue					39K -
depreciation and amortization	3.57K -	15K 319.82%	18K 20%	27K 50%	39K 44.44%
ebitda	-5.88M -	-17.26M 193.45%	-32.03M 85.55%	-94.55M 195.21%	-40.30M 57.38%
eps	-0.25 -	-1.04 316%	-2.64 153.85%	-4.09 54.92%	-1.34 67.24%
eps diluted	-0.25 -	-1.04 316%	-2.64 153.85%	-4.09 54.92%	-1.34 67.24%
general and administrative expenses	816 -	1.80M 220,488.24%	8.45M 369.50%	15.83M 87.34%	14.90M 5.86%
gross profit					-39K -
income before tax	-5.88M -	-17.27M 193.52%	-32.04M 85.57%	-95.06M 196.69%	-45.67M 51.95%
income tax expense	-8.82K -			25K -	30K 20%
interest expense				479K -	4.17M 770.15%
interest income					3.90M -
net income	-5.88M -	-17.27M 193.52%	-32.04M 85.57%	-95.08M 196.76%	-45.70M 51.93%
operating expenses	5.88M -	17.28M 193.71%	32.05M 85.49%	94.55M 195.04%	40.30M 57.38%
operating income	-5.88M -	-17.28M 193.71%	-32.05M 85.49%	-94.55M 195.04%	-40.34M 57.34%
other expenses		11K -	7K 36.36%	-506K 7,328.57%	5.11M 1,109.29%
research and development expenses	5.34M -	15.48M 189.92%	23.59M 52.46%	78.72M 233.62%	25.43M 67.69%
revenue
selling and marketing expenses	543.18K -				-39K -
selling general and administrative expenses	544K -	1.80M 230.88%	8.45M 369.50%	15.83M 87.34%	14.87M 6.11%
total other income expenses net	-5.25K -	11K 309.52%	7K 36.36%	-506K 7,328.57%	-5.34M 954.55%
weighted average shs out	23.76M -	16.54M 30.40%	12.13M 26.63%	23.27M 91.77%	34.08M 46.46%
weighted average shs out dil	23.76M -	16.54M 30.40%	12.13M 26.63%	23.27M 91.77%	34.08M 46.46%

COM:ELEVATIONONCOLOGY

Elevation Oncology, Inc.

Last Close

0.69

13/11 21:00

Market Cap

144.25M

Beta: -

Volume Today

784.24K

Avg: -

Preview